Promising immunotherapy: Highlighting cytokine-induced killer cells.
cancer
combined modality therapy
cytokine-induced killer cells
immunotherapy
Journal
Journal of cellular biochemistry
ISSN: 1097-4644
Titre abrégé: J Cell Biochem
Pays: United States
ID NLM: 8205768
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
received:
11
09
2018
accepted:
22
10
2018
pubmed:
18
12
2018
medline:
22
7
2020
entrez:
18
12
2018
Statut:
ppublish
Résumé
For many years, cancer therapy has appeared to be a challenging issue for researchers and physicians. By the introduction of novel methods in immunotherapy, the prospect of cancer therapy even more explained than before. Cytokine-induced killer (CIK) cell-based immunotherapy demonstrated to have potentiality in improving clinical outcomes and relieving major side effects of standard treatment options. In addition, given the distinctive features such as high safety, low toxicity effects on healthy cells, numerous clinical trials conducted on CIK cells. Due to the shortcomings that observed in CIK cell immunotherapy alone, arising a tendency to make modifications (combined modality therapy or combination therapy) including the addition of various types of cytokines, genetic engineering, combination with immune checkpoints, and so on. In this review, we have tried to bring forth the latest immunotherapy methods and their overview. We have discussed the combination therapies with CIK cells and the conducted clinical trials. This helps the future studies to use integrated therapies with CIK cells as a promising treatment of many types of cancers.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
8863-8883Informations de copyright
© 2018 Wiley Periodicals, Inc.